参考文献/References:
[1] Minner SA,Simone P,Chung BB,et al. Successful reversal of bradycardia and dyspnea with aminophylline after ticagrelor load[J]. J Pharm Pract, 2018,31(1):112-114.
[2] Bonaca MP,Bhatt DL,Oude Ophuis T,et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial[J]. JAMA Cardiol, 2016,1(4):425-432.
[3] Cannon CP,Husted S,Harrington RA,et al. Safety,tolerability,and initial efficacy of AZD6140,the first reversible oral adenosine diphosphate receptor antagonist,compared with clopidogrel,in patients with non-ST-segment elevation acute coronary syndrome:primary results of the DISPERSE-2 trial[J]. J Am Coll Cardiol,2007,50(19):1844-1851.
[4] Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057.
[5] Goto S,Huang CH,Park SJ,et al. Ticagrelor vs. clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome—Randomized,double-blind,phaseⅢPHILO study[J]. Circ J, 2015,79(11):2452-2460.
[6] Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800.
[7] Hiatt WR,Fowkes FG,Heizer G,et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease[J]. N Engl J Med,2017,376(1):32-40.
[8] Wong K,Amarenco P,Albers GW,et al. Efficacy and safety of ticagrelor in relation to aspirin use within the week before randomization in the SOCRATES trial[J]. Stroke,2018,49(7):1678-1685.
[9] Berwanger O,Lopes RD,Moia D,et al. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis:TREAT trial[J]. J Am Coll Cardiol, 2019,73(22):2819-2828.
[10] Bhatt DL,Steg PG,Mehta SR,et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention(THEMIS-PCI): a phase 3,placebo-controlled,randomised trial[J]. Lancet,2019,394(10204):1169-1180.
[11] Schunkert H,Boening A,von Scheidt M,et al. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting:the TiCAB trial[J]. Eur Heart J,2019,40(29):2432-2440.
[12] Turgeon RD,Fernandes KA,Juurlink D,et al. Ticagrelor and bradycardia:a nested case-control study[J]. Pharmacoepidemiol Drug Saf,2015,24(12):1281-1285.
[13] Bonello L,Laine M,Kipson N,et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome[J]. J Am Coll Cardiol,2014,63(9):872-877.
[14] Nylander S,Femia EA,Scavone M,et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism[J]. J Thromb Haemost, 2013,11(10):1867-1876.
[15] van Giezen JJ,Sidaway J,Glaves P,et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model[J]. J Cardiovasc Pharmacol Ther,2012,17(2):164-172.
[16] Wittfeldt A,Emanuelsson H,Brandrup-Wognsen G,et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans[J]. J Am Coll Cardiol,2013,61(7):723-727.
[17] Scirica BM,Cannon CP,Emanuelsson H,et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(Platelet Inhibition and Patient Outcomes) trial:results of the continuous electrocardiographic assessment substudy[J]. J Am Coll Cardiol,2011,57(19):1908-1916.
[18] Pujade I,Perino J,Mathieu C,et al. Risk of bradyarrhythmia related to ticagrelor:a systematic review and meta-analysis[J]. Pharmacol Res,2020,160:105089.
[19] Nicol M,Deblaise J,Choussat R,et al. Side effects of ticagrelor:sinus node dysfunction with ventricular pause[J]. Int J Cardiol,2015,191:56-57.
[20] Baker NC,Nadour W,Friehling M. Clinically significant ticagrelor induced conduction abnormalities following percutaneous coronary intervention[J]. Int J Cardiol,2016,214:21-22.
[21] 杨林承,汪羚利,聂丹,等. 替格瑞洛致房室传导阻滞一例并文献复习[J].中国心血管杂志,2019,24(6):559-561.
[22] Movahed MR. Diabetes as a risk factor for cardiac conduction defects:a review[J]. Diabetes Obes Metab,2007,9(3):276-281.
[23] Guzman E,Singh N,Khan IA,et al. Left bundle branch block in type 2 diabetes mellitus:a sign of advanced cardiovascular involvement[J]. Ann Noninvasive Electrocardiol,2004,9(4):362-365.
[24] 韩雅玲. 替格瑞洛临床应用中国专家共识[J].中华心血管病杂志,2016,44(2):112-120.
[25] Rosset S,Müller O,Pruvot E,et al. Prolonged asystole after a loading dose of ticagrelor[J]. Ann Intern Med,2018,168(8):602-603.
[26] 李秀艳,张文锐,柳杨,等. 替格瑞洛致心律失常不良反应文献分析[J].中国医院药学杂志,2020,40(6):699-703.
[27] Tsushima T,Sahadevan J,Intini A. Syncope after percutaneous coronary intervention[J]. JAMA Cardiol,2019,4(11):1170-1171.
[28] de Maria E,Borghi A,Modonesi L,et al. Ticagrelor therapy and atrioventricular block:do we need to worry?[J]. World J Clin Cases,2017,5(5):178-182.
[29] Yurtdas M,Ozdemir M. Ticagrelor-associated conduction disorder: a case report and review of the literature[J]. Cardiol Res,2017,8(3):123-127.
[30] di Serafino L,Rotolo FL,Boggi A,et al. Potential additive effects of ticagrelor,ivabradine,and carvedilol on sinus node[J]. Case Rep Cardiol,2014,2014:932595.
[31] 袁吉祥,张保和,刘玮. 替格瑞洛致高度房室阻滞合并心室停搏一例[J].中国循环杂志,2019,34(10):1025-1027.
[32] Goldberg A,Rosenfeld I,Nordkin I,et al. Life-threatening complete atrioventricular block associated with ticagrelor therapy[J]. Int J Cardiol,2015,182:379-380.
[33] Goldberg A,Rosenfeld I,Nordkin I,et al. Ticagrelor therapy in patients with advanced conduction disease:is it really safe?[J]. Int J Cardiol,2016,202:948-949.
[34] ?nlü M,Demirkol S,Yildirim AO,et al. Atrioventricular block associated with ticagrelor therapy may require permanent pacemaker[J]. Int J Cardiol,2016,202:946-947.
相似文献/References:
[1]陈艳,综述,袁晋青,等.替格瑞洛临床应用新进展[J].心血管病学进展,2016,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
CHEN Yan,YUAN Jinqing.The Updates of Ticagrelor Use in Clinical Practice[J].Advances in Cardiovascular Diseases,2016,(7):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
[2]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[3]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(7):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(7):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[8]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(7):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[9]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]
[10]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(7):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[11]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(7):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[12]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(7):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[13]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(7):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[14]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(7):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]